Bosh sahifaPBDA • FRA
add
Protalix Biotherapeutics Inc
Yopilish kursi
1,46 €
Kunlik diapazon
1,46 € - 1,51 €
Yillik diapazon
0,64 € - 2,70 €
Bozor kapitalizatsiyasi
132,94 mln USD
Oʻrtacha hajm
322,00
Narx/foyda
-
Dividend daromadliligi
-
Bozor yangiliklari
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (USD) | mar, 2025info | Y/Y qiyosi |
|---|---|---|
Daromad | 10,11 mln | 169,82% |
Joriy xarajat | 6,08 mln | 1,27% |
Sof foyda | -3,62 mln | 21,24% |
Sof foyda marjasi | -35,79 | 70,81% |
Har bir ulushga tushum | — | — |
EBITDA | -3,80 mln | 16,21% |
Amaldagi soliq stavkasi | 3,03% | — |
Balans
Jami aktivlari
Jami passivlari
| (USD) | mar, 2025info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 34,74 mln | -28,35% |
Jami aktivlari | 73,89 mln | -17,74% |
Jami passivlari | 28,68 mln | -52,22% |
Umumiy kapital | 45,21 mln | — |
Tarqatilgan aksiyalar | 79,61 mln | — |
Narxi/balansdagi bahosi | 2,52 | — |
Aktivlardan daromad | -14,07% | — |
Kapitaldan daromad | -20,90% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (USD) | mar, 2025info | Y/Y qiyosi |
|---|---|---|
Sof foyda | -3,62 mln | 21,24% |
Operatsiyalardan naqd pul | -5,06 mln | -220,77% |
Sarmoyadan naqd pul | -312,00 ming | 48,51% |
Moliyadan naqd pul | 5,08 mln | — |
Naqd pulning sof oʻzgarishi | -302,00 ming | -108,45% |
Boʻsh pul | -3,76 mln | -175,74% |
Haqida
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease. Wikipedia
CEO
Tashkil etilgan
1993
Bosh ofis
Sayt
Xodimlar soni
213
